2000 to 2019 Saw Rise in Breast Cancer Incidence in Young U.S. Women

2024-01-30
临床结果
TUESDAY, Jan. 30, 2024 -- There has been an increase in breast cancer incidence rates among young U.S. women from 2000 to 2019, according to a study published online Jan. 26 in JAMA Network Open.
Shuai Xu, M.P.H., from Washington University School of Medicine in St. Louis, and colleagues assessed recent trends and how period and cohort effects may affect trends in breast cancer incidence among young U.S. women (aged 20 to 49 years). The analysis included data from 217,815 women with a primary invasive breast cancer identified from the Surveillance, Epidemiology, and End Results registries (2000 to 2019).
The researchers found that the majority were diagnosed with an estrogen receptor (ER)-positive/progesterone receptor (PR)-positive tumor (61.5 percent) and were diagnosed with a stage I tumor (37.6 percent). There was an overall increase in incidence of invasive breast cancer (average annual percent changes [AAPC], 0.79), with similar trends seen across almost all racial and ethnic groups. Age-standardized incidence rates (ASIR) increased for ER-positive/PR-positive (AAPC, 2.72) and ER-positive/PR-negative tumors (AAPC, 1.43), but decreased for ER-negative/PR-positive tumors (AAPC, −3.25). ASIR were highest among non-Hispanic Black women (aged 20 to 29 years: incidence rate ratios [IRR], 1.53; aged 30 to 39 years: IRR, 1.15). However, for women aged 40 to 49 years, ASIR was lower for non-Hispanic Black women versus non-Hispanic White women (IRR, 0.96). Both cohort and period effects were seen on breast cancer incidence in an age-period-cohort analysis.
"These results suggest that understanding factors driving differential trends in incidence rates for different age groups by race and ER-positive status should provide insights into breast cancer prevention in young women," the authors write.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。